Ginkgo Bioworks Holdings, Inc. DNA
We take great care to ensure that the data presented and summarized in this overview for Ginkgo Bioworks Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DNA
View all-
Black Rock Inc. New York, NY42MShares$465 Million0.0% of portfolio
-
Titleist Asset Management, Ltd. San Antonio, TX2.31MShares$25.6 Million0.92% of portfolio
-
Putnam Investments LLC Boston, MA1.5MShares$16.6 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.15MShares$12.7 Million0.0% of portfolio
-
Benjamin F. Edwards & Company, Inc. St. Louis, MO235KShares$2.6 Million0.0% of portfolio
-
Aj Wealth Strategies, LLC197KShares$2.18 Million0.02% of portfolio
-
Pathstone Family Office, LLC Englewood, NJ162KShares$1.79 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V8102KShares$1.13 Million0.0% of portfolio
-
American Portfolios Advisors Holbrook, NY70.3KShares$778,2980.01% of portfolio
-
Rothschild Investment Corp61.9KShares$685,2330.01% of portfolio
Latest Institutional Activity in DNA
Top Purchases
Top Sells
About DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Insider Transactions at DNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 11
2025
|
Myrtle S Potter Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,822
+50.0%
|
-
|
|
Jun 11
2025
|
Harry Sloan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,822
+3.83%
|
-
|
|
Jun 11
2025
|
Kathy Hopinkah Hannan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,822
+41.91%
|
-
|
|
Jun 11
2025
|
Christian O Henry Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,822
+19.63%
|
-
|
|
Jun 11
2025
|
Sri Kosuri Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,067
+50.0%
|
-
|
|
Jun 11
2025
|
Shyam Sankar Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,822
+13.01%
|
-
|
|
Jun 11
2025
|
Ross Fubini Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,822
+50.0%
|
-
|
|
May 21
2025
|
Mark E. Dmytruk Officer |
SELL
Open market or private sale
|
Direct |
706
-1.5%
|
$4,942
$7.58 P/Share
|
|
May 21
2025
|
Steven P. Coen Officer |
SELL
Open market or private sale
|
Direct |
346
-3.62%
|
$2,422
$7.58 P/Share
|
|
May 20
2025
|
Mark E. Dmytruk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,479
+1.05%
|
-
|
|
May 20
2025
|
Steven P. Coen Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
743
+3.74%
|
-
|
|
Apr 21
2025
|
Mark E. Dmytruk Officer |
SELL
Open market or private sale
|
Direct |
1,244
-2.66%
|
$8,708
$7.28 P/Share
|
|
Apr 21
2025
|
Steven P. Coen Officer |
SELL
Open market or private sale
|
Direct |
997
-10.16%
|
$6,979
$7.28 P/Share
|
|
Apr 17
2025
|
Mark E. Dmytruk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,548
+1.1%
|
-
|
|
Apr 17
2025
|
Steven P. Coen Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,804
+5.97%
|
-
|
|
Mar 13
2025
|
Mark E. Dmytruk Officer |
BUY
Conversion of derivative security
|
Direct |
9,497
+17.7%
|
-
|
|
Mar 04
2025
|
Steven P. Coen Officer |
SELL
Open market or private sale
|
Direct |
395
-4.7%
|
$2,765
$7.72 P/Share
|
|
Mar 04
2025
|
Mark E. Dmytruk Officer |
SELL
Open market or private sale
|
Direct |
790
-2.23%
|
$5,530
$7.72 P/Share
|
|
Mar 03
2025
|
Steven P. Coen Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
743
+4.23%
|
-
|
|
Mar 03
2025
|
Mark E. Dmytruk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,479
+1.39%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 253K shares |
|---|---|
| Other acquisition or disposition | 240K shares |
| Conversion of derivative security | 9.5K shares |
| Open market or private sale | 93.3K shares |
|---|